EP-102

EP-102 is an investigational small molecule drug candidate developed by Pari Pharma for the treatment of asthma. It is designed as a dual-acting bronchodilator, targeting both muscarinic acetylcholine receptors (mAChRs) and the β2-adrenergic receptor. This pharmacological profile, commonly referred to as a Muscarinic Antagonist Beta-Agonist (MABA), aims to provide enhanced bronchodilation by simultaneously inhibiting cholinergic-induced bronchoconstriction and promoting β2-receptor-mediated relaxation of airway smooth muscle. The drug is intended for inhalation delivery, likely utilizing Pari Pharma's proprietary nebulizer technologies such as the eFlow system. As of early 2026, the program is listed in a pending status within the company's development pipeline.